Jill Clendening

Chief Patient Experience Officer David Haynes, MD, center, presented Excellence in Patient Experience awards to Cassandra Bruns, DNP, APRN, FNP-BC, left, and Inder Raj Grewal, MBBS, who had perfect top box scores of 100%. Not pictured is Bethany Sanders, MSN, CNM, who also received a perfect score. (Photo by Susan Urmy)
October 19, 2023

Patient Experience awards honor excellence of clinical teams and individual clinicians

October 17, 2023

Powers announces plan to step down from key diabetes leadership roles

Alvin C. Powers, MD, has announced plans to step down effective July 1, 2024, as director of the Vanderbilt Diabetes Center, director of the Vanderbilt Diabetes Research and Training Center, and chief of the Division of Diabetes, Endocrinology and Metabolism.

The research team includes, left to right, Bruno Scaglioni, PhD; Keith Obstein MD, MPH; James Martin, PhD; Claire Landewee, BS; Simone Calò, PhD; and Pietro Valdastri, PhD. (hoto by Susan Urmy)
October 17, 2023

VISE-affiliated researchers conduct phase 1 trial of novel magnetic endoscope for colonoscopies

A Vanderbilt research team is conducting the first phase 1 clinical trial of a magnetic, flexible endoscope that has the potential to provide a safer alternative to standard colonoscopy, particularly for individuals with inflammatory bowel disease.

October 17, 2023

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

October 12, 2023

Stevenson named chair of Department of Health Policy

David Stevenson has been named chair of the Department of Health Policy at Vanderbilt University Medical Center.

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)
September 28, 2023

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.